Skip to main content

What the label lists and what reports show

Cefiderocol side effects

Cefiderocol's FDA label: “Common Adverse Reactions Table 4 lists the most common selected adverse reactions occurring in ≥ 2% of cUTI patients receiving FETROJA in Trial 1.” FAERS holds 303 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is drug resistance (31 reports).

  • No generic listed

Check it at the source: the cefiderocol FDA label on DailyMed (effective February 24, 2026, Shionogi Inc.); the FDA FAERS public dashboard.

What does the label list?

From the label: adverse reactions

Common Adverse Reactions Table 4 lists the most common selected adverse reactions occurring in ≥ 2% of cUTI patients receiving FETROJA in Trial 1.

Table 4 Selected Adverse Reactions Occurring in ≥ 2% of cUTI Patients Receiving FETROJA in Trial 1

Adverse ReactionFETROJA 2 grams IV over 1 hour every 8 hours (with dosing adjustment based on renal…Imipenem/Cilastatin 1 gram IV over 1 hour every 8 hours (with dosing adjustment based on…
Diarrhea4%6%
Infusion site reactions Infusion site reactions include infusion site erythema,…4%5%
Constipation3%4%
Rash Rash includes rash macular, rash maculopapular, erythema, skin irritation.3%< 1%
Candidiasis Candidiasis includes oral or vulvovaginal candidiasis, candiduria.2%3%
Cough2%< 1%
Elevations in liver tests Elevations in liver tests include alanine aminotransferase,…2%< 1%
Headache2%5%
Hypokalemia Hypokalemia includes blood potassium decreased.2%3%
Nausea2%4%
Vomiting2%1%

Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.

From the label: adverse reactions, continued

The following serious adverse reactions are described in greater detail in the Warnings and Precautions section: Increase in All-Cause Mortality in Patients with Carbapenem-Resistant Gram-Negative Bacterial Infections [see Warnings and Precautions (5.1) ] Hypersensitivity Reactions [see Warnings and Precautions (5.2) ] Clostridioides difficile -associated Diarrhea (CDAD) [see Warnings and Precautions (5.3) ] Seizures and Other Central Nervous System Adverse Reactions [see Warnings and Precautions (5.4) ] cUTI: The most frequently occurring adverse reactions in greater than or equal to 2% of cUTI patients treated with FETROJA were diarrhea, infusion site reactions, constipation, rash, candidiasis, cough, elevations in liver tests, headache, hypokalemia, nausea, and vomiting. ( 6.1 ) HABP/VABP: The most frequently occurring adverse reactions in greater than or equal to 4% of HABP/VABP patients treated with FETROJA were elevations in liver tests, hypokalemia, diarrhea, hypomagnesemia, and atrial fibrillation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Shionogi Inc. at 1-800-849-9707 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. …

Source: FDA drug label, Shionogi Inc., effective February 24, 2026 (SPL set 75c0c785-38e0-4049-a6fb-b77581f5b35c), via openFDA; the full label on DailyMed

What do FAERS reports show?

303 reports list cefiderocol among the medicines taken, each a report of something that happened, not proof the medicine caused it; 145 are coded as a death and 61 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 16 reactions below, 6 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.

The 25 most reported reactions

  • Death (an outcome recorded in the report)71
  • Drug Resistance31
  • Treatment Failure (a use or a product term, not a reaction)27
  • Off Label Use (a use or a product term, not a reaction)24
  • Acute Kidney Injury20
  • Pathogen Resistance17
  • Multiple Organ Dysfunction Syndrome14
  • Hepatic Cytolysis13
  • Infection (a use or a product term, not a reaction)13
  • Condition Aggravated (a use or a product term, not a reaction)11
  • Septic Shock11
  • Cholestasis (named in the label)10
  • Encephalopathy (named in the label)10
  • No Adverse Event (a use or a product term, not a reaction)10
  • Sepsis (named in the label)9
  • Chromaturia (named in the label)8
  • Pneumonia (a use or a product term, not a reaction)8
  • Product Storage Error7
  • Drug Effect Less Than Expected6
  • Drug Ineffective (a use or a product term, not a reaction)6
  • Incorrect Product Administration Duration6
  • Medication Error (a use or a product term, not a reaction)6
  • Thrombocytopenia (named in the label)6
  • Bradycardia (named in the label)5
  • Generalised Tonic-Clonic Seizure5

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms

What next?

Cefiderocol: the full record
label, generics, price, shortages, recalls
Side effects hub
the most reported medicines and reactions